Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study
European Journal of Cancer2017Vol. 85, pp. 39–48
Citations Over Time
Alain Ravaud, Carlos Gomez‐Roca, Marie-Quitterie Picat, Laurence Digue, Christine Chevreau, Anne Gimbert, Emmanuelle Chauzit, Rémi Sitta, F. Cornélis, Julien Asselineau, R. Aziza, Amaury Daste, Cathy Quemener, Jessica Baud, Andréas Bikfalvi, Delphine Pedenon–Périchout, A. Doussau, Mathiéu Molimard, Jean‐Pierre Delord
Related Papers
- → mTOR pathway inhibition in renal cell carcinoma(2010)12 cited
- → First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium(2014)12 cited
- → Difference in adverse-event profiles between mTOR inhibitors, temsirolimus, and everolimus for advanced renal cell carcinoma.(2013)3 cited
- → The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma(2018)3 cited
- → Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma(2009)2 cited